• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ILA
Click for more information
0.00% 6.6¢

ISLAND PHARMACEUTICALS LIMITED - Corporate Spotlight

Market Cap $8.367M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Island Pharmaceuticals Limited is an Australia-based drug repurposing company, focused on... Island Pharmaceuticals Limited is an Australia-based drug repurposing company, focused on areas of need for antiviral therapeutics to address infectious diseases. The Company's lead asset is ISLA-101, a drug, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
6.6¢ 		Change
0.000(0.00%) 		Mkt cap ! $8.367M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
3 48127 6.0¢
 

Sellers (Offers)

Price($) Vol. No.
6.6¢ 153105 2
View Market Depth
Last trade - 16.12pm 23/08/2024 (20 minute delay) ?
ILA (ASX) Chart

Top Stories

Raiden gears up for exploration in final quarter of 2024

Raiden Resources Ltd - which is exploration for a multiplicity of minerals in the Pilbara region of WA - is looking ahead to a busy schedule.
Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions Given the recent fall in iron ore prices below the $100 mark, now might be the time to buy into specialised stocks in the materials sector.
IPH raises $100M to buy up Canadian IP firm Bereskin & Parr IPH Ltd has raised $100 million in an institutional placement to support the acquisition, while also launching a share purchase plan.
Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt Noronex Limited (ASX:NRX) has kicked off a gravity EM survey at the Damara project in Namibia – part of its earn-in deal with South32.
Reporting wrap: Inghams, Accent, Mayne Pharma Inghams Group Ltd, Accent Group Ltd and Mayne Pharma Group Ltd all reported final year results for the 2024 fiscal year.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.